Effect of Alternative Aluminum Adjuvants on the Absorption and Immunogenicity of HPV16 L1 VLPs in Mice

Aluminum adjuvants are commonly used in prophylactic vaccines to enhance antigen immunogenicity through induction of high-titer antibody responses. Three major forms of aluminum adjuvants with substantially different physical and chemical properties have been described: aluminum phosphate (AlPO4), aluminum hydroxide (AlOH) and amorphous aluminum hydroxyphosphate sulfate (AAHS). Here we describe the effect of these different aluminum adjuvants on the formulation and subsequent immunogenicity in mice of virus-like particles (VLPs) consisting of the L1 protein of Human Papillomavirus (HPV) Type 16. Electron microscopy demonstrated that the physical appearance of the phosphate-containing aluminum adjuvants was markedly different from that of aluminum hydroxide. All three aluminum adjuvants were found to display unique surface charge profiles over a range of pH, while AAHS demonstrated the greatest inherent capacity for adsorption of L1 VLPs. These differences were associated with differences in immunogenicity: anti-HPV L1 VLP responses from mice immunized with AAHS-formulated HPV16 vaccine were substantially greater than those produced by mice immunized with the same antigen formulated with aluminum hydroxide. In addition, HPV L1 VLPs formulated on AAHS also induced a substantial interferon-gamma secreting T cell response to L1 peptides indicating the potential for an enhanced memory response to this antigen. These results indicate that the chemical composition of aluminum adjuvants can have a profound influence on the magnitude and quality of the immune response to HPV VLP vaccines.

[1]  J. White,et al.  Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. , 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[2]  F. Regnier,et al.  Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. , 1994, Vaccine.

[3]  J. White,et al.  Structure and properties of aluminum-containing adjuvants. , 1995, Pharmaceutical biotechnology.

[4]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[5]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[6]  D. Volkin,et al.  Ultraviolet absorption spectroscopy. , 1995, Methods in molecular biology.

[7]  F. Vogel,et al.  A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.

[8]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[9]  M. Rosolowsky,et al.  Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. , 1995, Vaccine.

[10]  R. Wagner,et al.  Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. , 1996, Virology.

[11]  N. Christensen,et al.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.

[12]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[13]  A. Sher,et al.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. , 1997, Journal of immunology.

[14]  M. Suckow,et al.  In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. , 1997, Vaccine.

[15]  K. Jansen,et al.  Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. , 1999, Protein expression and purification.

[16]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[17]  N. Muñoz,et al.  Human papillomavirus and cancer: the epidemiological evidence. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  F. Authier,et al.  Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. , 2001, Brain : a journal of neurology.

[19]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[20]  H. HogenEsch,et al.  Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.

[21]  W. Mcclements,et al.  Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. , 2003, Vaccine.

[22]  Xu Liu,et al.  Adjuvant synergy in the response to hepatitis B vaccines. , 2003, Vaccine.

[23]  E. B. Lindblad Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[24]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[25]  S. Hem,et al.  Aluminum Compounds Used as Adjuvants in Vaccines , 1990, Pharmaceutical Research.

[26]  M. Caulfield,et al.  Identification of T-cell epitopes using ELISpot and peptide pool arrays. , 2004, Methods in molecular medicine.

[27]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[28]  W. Mcclements,et al.  Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant , 2005, Journal of immune based therapies and vaccines.

[29]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[30]  K. Jansen,et al.  Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). , 2006, Journal of pharmaceutical sciences.

[31]  J. Brewer (How) do aluminium adjuvants work? , 2006, Immunology letters.

[32]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[33]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[34]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[35]  M. Kosinski,et al.  GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.